Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins

Details for Australian Patent Application No. 2004272072 (hide)

Owner Wyeth LLC ETEX Corporation

Inventors Seeherman, Howard; Li, Rebecca; Kim, Hyun

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004272072

PCT Pub. Number WO2005/025595

Priority 60/502,493 12.09.03 US

Filing date 10 September 2004

Wipo publication date 24 March 2005

Acceptance publication date 8 July 2010

International Classifications

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61L 24/00 (2006.01) Surgical adhesives or cements

A61L 27/22 (2006.01) Materials for prostheses or for coating prostheses

A61L 27/42 (2006.01) Materials for prostheses or for coating prostheses

A61L 27/46 (2006.01) Materials for prostheses or for coating prostheses

A61L 27/50 (2006.01) Materials for prostheses or for coating prostheses

Event Publications

23 March 2006 PCT application entered the National Phase

  PCT publication WO2005/025595 Priority application(s): WO2005/025595

3 June 2010 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the names Etex Corporation and Wyeth Holdings Corporation, Application No. 2004272072, under INID (71), correct the co-applicant to read Wyeth

8 July 2010 Application Accepted

  Published as AU-B-2004272072

4 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272077-Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

2004272066-Methods of using WISP antagonists